No retraction, correction or concern found when last checked on Oct 31, 2026.

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

Bryan E. Jones, Patricia L. Brown-Augsburger, Kizzmekia S. Corbett and 54 more

Science Translational Medicine · 2021 · CC BY

doi:10.1126/scitranslmed.abf1906

Abstract

LY-CoV555, a SARS-CoV-2 spike protein–specific antibody, neutralizes SARS-CoV-2 and protects the airways of nonhuman primates against infection.

References 87

1.
M. McKee, D. Stuckler, If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future. Nat. Med. 26, 640–642 (2020 ).
Not in our library10.1038/s41591-020-0863-y
2.
C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020 ).
Not in our library10.1016/s0140-6736(20)30183-5
3.
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses · 2020
Corrected
4.
Factors associated with COVID-19-related death using OpenSAFELY · 2020
No notice
5.
P. Gilchuk, R. G. Bombardi, J. H. Erasmus, Q. Tan, R. Nargi, C. Soto, P. Abbink, T. J. Suscovich, L. A. Durnell, A. Khandhar, J. Archer, J. Liang, M. E. Fouch, E. Davidson, B. J. Doranz, T. Jones, E. Larson, S. Ertel, B. Granger, J. Fuerte-Stone, V. Roy, T. Broge, T. C. Linnekin, C. H. Linde, M. J. Gorman, J. Nkolola, G. Alter, S. G. Reed, D. H. Barouch, M. S. Diamond, J. E. Crowe Jr., N. Van Hoeven, L. B. Thackray, R. H. Carnahan, Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics. Nat. Biomed. Eng. 4, 1030–1043 (2020 ).
Not in our library10.1038/s41551-020-0594-x
6.
B. Kelley, Developing therapeutic monoclonal antibodies at pandemic pace. Nat. Biotechnol. 38, 540–545 (2020 ).
Not in our library10.1038/s41587-020-0512-5
7.
S. J. Zost, P. Gilchuk, J. B. Case, E. Binshtein, R. E. Chen, J. P. Nkolola, A. Schäfer, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, D. R. Martinez, L. E. Williamson, E. C. Chen, T. Jones, S. Day, L. Myers, A. O. Hassan, N. M. Kafai, E. S. Winkler, J. M. Fox, S. Shrihari, B. K. Mueller, J. Meiler, A. Chandrashekar, N. B. Mercado, J. J. Steinhardt, K. Ren, Y.-M. Loo, N. L. Kallewaard, B. T. McCune, S. P. Keeler, M. J. Holtzman, D. H. Barouch, L. E. Gralinski, R. S. Baric, L. B. Thackray, M. S. Diamond, R. H. Carnahan, J. E. Crowe Jr., Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443–449 (2020 ).
Not in our library10.1038/s41586-020-2548-6
8.
J. Shang, G. Ye, K. Shi, Y. Wan, C. Luo, H. Aihara, Q. Geng, A. Auerbach, F. Li, Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221–224 (2020 ).
Not in our library10.1038/s41586-020-2179-y
9.
F. Li, W. Li, M. Farzan, S. C. Harrison, Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309, 1864–1868 (2005 ).
Not in our library10.1126/science.1116480
10.
W. Li, M. J. Moore, N. Vasilieva, J. Sui, S. K. Wong, M. A. Berne, M. Somasundaran, J. L. Sullivan, K. Luzuriaga, T. C. Greenough, H. Choe, M. Farzan, Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450–454 (2003 ).
Not in our library10.1038/nature02145
11.
D. J. Benton, A. G. Wrobel, P. Xu, C. Roustan, S. R. Martin, P. B. Rosenthal, J. J. Skehel, S. J. Gamblin, Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588, 327–330 (2020 ).
Not in our library10.1038/s41586-020-2772-0
12.
L. Liu, P. Wang, M. S. Nair, J. Yu, M. Rapp, Q. Wang, Y. Luo, J. F. W. Chan, V. Sahi, A. Figueroa, X. V. Guo, G. Cerutti, J. Bimela, J. Gorman, T. Zhou, Z. Chen, K.-Y. Yuen, P. D. Kwong, J. G. Sodroski, M. T. Yin, Z. Sheng, Y. Huang, L. Shapiro, D. D. Ho, Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450–456 (2020 ).
Not in our library10.1038/s41586-020-2571-7
13.
R. Shi, C. Shan, X. Duan, Z. Chen, P. Liu, J. Song, T. Song, X. Bi, C. Han, L. Wu, G. Gao, X. Hu, Y. Zhang, Z. Tong, W. Huang, W. J. Liu, G. Wu, B. Zhang, L. Wang, J. Qi, H. Feng, F.-S. Wang, Q. Wang, G. F. Gao, Z. Yuan, J. Yan, A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120–124 (2020 ).
Not in our library10.1038/s41586-020-2381-y
14.
M. Tuccori, S. Ferraro, I. Convertino, E. Cappello, G. Valdiserra, C. Blandizzi, F. Maggi, D. Focosi, Anti-SARS-CoV-2 neutralizing monoclonal antibodies: Clinical pipeline. MAbs 12, 1854149 (2020 ).
Not in our library10.1080/19420862.2020.1854149
15.
SARS-CoV-2 infection protects against rechallenge in rhesus macaques · 2020
No notice
16.
V. J. Munster, F. Feldmann, B. N. Williamson, N. van Doremalen, L. Pérez-Pérez, J. Schulz, K. Meade-White, A. Okumura, J. Callison, B. Brumbaugh, V. A. Avanzato, R. Rosenke, P. W. Hanley, G. Saturday, D. Scott, E. R. Fischer, E. de Wit, Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature 585, 268–272 (2020 ).
Not in our library10.1038/s41586-020-2324-7
17.
Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model · 2020
No notice
18.
DNA vaccine protection against SARS-CoV-2 in rhesus macaques · 2020
No notice
19.
P. Yu, F. Qi, Y. Xu, F. Li, P. Liu, J. Liu, L. Bao, W. Deng, H. Gao, Z. Xiang, C. Xiao, Q. Lv, S. Gong, J. Liu, Z. Song, Y. Qu, J. Xue, Q. Wei, M. Liu, G. Wang, S. Wang, H. Yu, X. Liu, B. Huang, W. Wang, L. Zhao, H. Wang, F. Ye, W. Zhou, W. Zhen, J. Han, G. Wu, Q. Jin, J. Wang, W. Tan, C. Qin, Age-related rhesus macaque models of COVID-19. Animal Models Exp. Med. 3, 93–97 (2020 ).
Not in our library10.1002/ame2.12108
20.
L. Bao, W. Deng, H. Gao, C. Xiao, J. Liu, J. Xue, Q. Lv, J. Liu, P. Yu, Y. Xu, F. Qi, Y. Qu, F. Li, Z. Xiang, H. Yu, S. Gong, M. Liu, G. Wang, S. Wang, Z. Song, Y. Liu, W. Zhao, Y. Han, L. Zhao, X. Liu, Q. Wei, C. Qin, Lack of reinfection in rhesus macaques infected with SARS-CoV-2. bioRxiv 10.1101/2020.03.13.990226 (2020 ).
Not in our library
21.
I. Messaoudi, R. Estep, B. Robinson, S. W. Wong, Nonhuman primate models of human immunology. Antioxid. Redox Signal. 14, 261–273 (2011 ).
Not in our library10.1089/ars.2010.3241
22.
P. Chen, A. Nirula, B. Heller, R. L. Gottlieb, J. Boscia, J. Morris, G. Huhn, J. Cardona, B. Mocherla, V. Stosor, I. Shawa, A. C. Adams, J. Van Naarden, K. L. Custer, L. Shen, M. Durante, G. Oakley, A. E. Schade, J. Sabo, D. R. Patel, P. Klekotka, D. M. Skovronsky; BLAZE-1 Investigators, SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N. Engl. J. Med. 384, 229–237 (2020 ).
Not in our library10.1056/nejmoa2029849
23.
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model · 2020
No notice
24.
J. Lan, J. Ge, J. Yu, S. Shan, H. Zhou, S. Fan, Q. Zhang, X. Shi, Q. Wang, L. Zhang, X. Wang, Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–220 (2020 ).
Not in our library10.1038/s41586-020-2180-5
25.
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 · 2020
No notice
26.
J. Misasi, M. S. Gilman, M. Kanekiyo, M. Gui, A. Cagigi, S. Mulangu, D. Corti, J. E. Ledgerwood, A. Lanzavecchia, J. Cunningham, J. J. Muyembe-Tamfun, U. Baxa, B. S. Graham, Y. Xiang, N. J. Sullivan, J. S. McLellan, Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351, 1343–1346 (2016 ).
Not in our library10.1126/science.aad6117
27.
S. Mulangu, L. E. Dodd, R. T. Davey Jr., O. T. Mbaya, M. Proschan, D. Mukadi, M. L. Manzo, D. Nzolo, A. T. Oloma, A. Ibanda, R. Ali, S. Coulibaly, A. C. Levine, R. Grais, J. Diaz, H. C. Lane, J. J. Muyembe-Tamfum; PALM Writing Group, B. Sivahera, M. Camara, R. Kojan, R. Walker, B. Dighero-Kemp, H. Cao, P. Mukumbayi, P. Mbala-Kingebeni, S. Ahuka, S. Albert, T. Bonnett, I. Crozier, M. Duvenhage, C. Proffitt, M. Teitelbaum, T. Moench, J. Aboulhab, K. Barrett, K. Cahill, K. Cone, R. Eckes, L. Hensley, B. Herpin, E. Higgs, J. Ledgerwood, J. Pierson, M. Smolskis, Y. Sow, J. Tierney, S. Sivapalasingam, W. Holman, N. Gettinger, D. Vallée, J. Nordwall; PALM Consortium Study Team, A randomized, controlled trial of ebola virus disease therapeutics. N. Engl. J. Med. 381, 2293–2303 (2019 ).
Not in our library10.1056/nejmoa1910993
28.
R. Deng, S. Iyer, F.-P. Theil, D. L. Mortensen, P. J. Fielder, S. Prabhu, Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned? MAbs 3, 61–66 (2011 ).
Not in our library10.4161/mabs.3.1.13799
29.
J. Q. Dong, D. H. Salinger, C. J. Endres, J. P. Gibbs, C.-P. Hsu, B. J. Stouch, E. Hurh, M. Gibbs, Quantitative prediction of human pharmacokinetics for monoclonal antibodies: Retrospective analysis of monkey as a single species for first-in-human prediction. Clin. Pharmacokinet. 50, 131–142 (2011 ).
Not in our library10.2165/11537430-000000000-00000
30.
H. C. Kaulbach, M. V. White, Y. Igarashi, B. K. Hahn, M. A. Kaliner, Estimation of nasal epithelial lining fluid using urea as a marker. J. Allergy Clin. Immunol. 92, 457–465 (1993 ).
Not in our library10.1016/0091-6749(93)90125-y
31.
Z. Magyarics, F. Leslie, J. Bartko, H. Rouha, S. Luperchio, C. Schörgenhofer, M. Schwameis, U. Derhaschnig, H. Lagler, L. Stiebellehner, C. Firbas, S. Weber, E. Campanaro, B. Jilma, E. Nagy, C. Stevens, Randomized, double-blind, placebo-controlled, single-ascending-dose study of the penetration of a monoclonal antibody combination (ASN100) targeting Staphylococcus aureus cytotoxins in the lung epithelial lining fluid of healthy volunteers. Antimicrob. Agents Chemother. 63, 00350-19 (2019 ).
Not in our library10.1128/aac.00350-19
32.
S. J. Zost, P. Gilchuk, R. E. Chen, J. B. Case, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, E. C. Chen, E. Binshtein, S. Shrihari, M. Ostrowski, H. Y. Chu, J. E. Didier, K. W. MacRenaris, T. Jones, S. Day, L. Myers, F. E.-H. Lee, D. C. Nguyen, I. Sanz, D. R. Martinez, P. W. Rothlauf, L.-M. Bloyet, S. P. J. Whelan, R. S. Baric, L. B. Thackray, M. S. Diamond, R. H. Carnahan, J. E. Crowe Jr., Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat. Med. 26, 1422–1427 (2020 ).
Not in our library10.1038/s41591-020-0998-x
33.
M.-C. Rouan, T. Gevers, D. Roymans, L. de Zwart, D. Nauwelaers, M. De Meulder, P. van Remoortere, M. Vanstockem, A. Koul, K. Simmen, K. Andries, Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model. Antimicrob. Agents Chemother. 54, 4534–4539 (2010 ).
Not in our library10.1128/aac.00643-10
34.
D. Wrapp, N. Wang, K. S. Corbett, J. A. Goldsmith, C.-L. Hsieh, O. Abiona, B. S. Graham, J. S. McLellan, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020 ).
Not in our library10.1126/science.abb2507
35.
M. Pelegrin, M. Naranjo-Gomez, M. Piechaczyk, Antiviral monoclonal antibodies: Can they be more than simple neutralizing agents? Trends Microbiol. 23, 653–665 (2015 ).
Not in our library10.1016/j.tim.2015.07.005
36.
S. Johnson, C. Oliver, G. A. Prince, V. G. Hemming, D. S. Pfarr, S. C. Wang, M. Dormitzer, J. O’Grady, S. Koenig, J. K. Tamura, R. Woods, G. Bansal, D. Couchenour, E. Tsao, W. C. Hall, J. F. Young, Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176, 1215–1224 (1997 ).
Not in our library10.1086/514115
37.
J. Braun, L. Loyal, M. Frentsch, D. Wendisch, P. Georg, F. Kurth, S. Hippenstiel, M. Dingeldey, B. Kruse, F. Fauchere, Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. medRxiv 10.1101/2020.04.17.20061440 (2020 ).
Not in our library10.1038/s41586-020-2598-9
38.
Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020 · 2021
No notice
39.
H. Tegally, E. Wilkinson, M. Giovanetti, A. Iranzadeh, V. Fonseca, J. Giandhari, D. Doolabh, S. Pillay, E. J. San, N. Msomi, K. Mlisana, A. von Gottberg, S. Walaza, M. Allam, A. Ismail, T. Mohale, A. J. Glass, S. Engelbrecht, G. Van Zyl, W. Preiser, F. Petruccione, A. Sigal, D. Hardie, G. Marais, M. Hsiao, S. Korsman, M.-A. Davies, L. Tyers, I. Mudau, D. York, C. Maslo, D. Goedhals, S. Abrahams, O. Laguda-Akingba, A. Alisoltani-Dehkordi, A. Godzik, C. K. Wibmer, B. T. Sewell, J. Lourenço, L. C. J. Alcantara, S. L. K. Pond, S. Weaver, D. Martin, R. J. Lessells, J. N. Bhiman, C. Williamson, T. de Oliveira, Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv 10.1101/2020.12.21.20248640 (2020 ).
Not in our library
40.
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016 · 2021
No notice

All 87 references

Cited by papers we hold 25

Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans · 2024
No notice
The development of COVID-19 treatment · 2023
No notice
Antibody evasion properties of SARS-CoV-2 Omicron sublineages · 2022
No notice
Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies · 2022
No notice
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming? · 2022
Not checked
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies · 2022
No notice
Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater · 2022
Corrected
An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain · 2022
No notice
Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529 · 2022
No notice
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection · 2022
No notice
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5 · 2022
No notice
Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody · 2022
No notice
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant · 2022
No notice
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans · 2022
No notice
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection · 2022
No notice
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy · 2021
No notice
Current status of structure-based drug repurposing against COVID-19 by targeting SARS-CoV-2 proteins · 2021
Not checked
Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency · 2021
Not checked
A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants · 2021
Not checked
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016 · 2021
No notice

and 5 more

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.